Title | Efficacy of silver needle therapy for the treatment of chronic nonspecific low back pain: a prospective, single-center, randomized, parallel-controlled clinical trial. | ||
Author | Hu, Xuesong; Dong, Shaoxing; Zhang, Bing; Wang, Xuan; Yin, Yanwei; Liu, Chuansheng; Yu, Junmin; Wu, Xing; Xu, Fenghu; Meng, Chao | ||
Journal | Trials | Publication Year/Month | 2021-Jan |
PMID | 33478570 | PMCID | PMC7818943 |
Affiliation + expend | 1.Department of Pain, the People's Hospital of Yuxi City, The 6th Affiliated Hospital of Kunming Medical University, Yuxi, China. |
BACKGROUND: Chronic nonspecific low back pain (CNSLBP) troubles approximately 30% of people worldwide. Silver needle therapy (SNT) is a treatment method to relieve soft tissue pain through heating. Therefore, this study aimed to observe the effects of SNT on CNSLBP. METHODS: In this study, 100 patients were randomly divided into 2 groups: silver needle (SN) group and control group (n = 50). In the SN group, patients received SNT and physiotherapy, while patients received physiotherapy alone in the control group. At the 6-month follow-up, the numerical rating scale (NRS), Oswestry Disability Index (ODI), Short-Form 12 of quality of life (SF-12), the natural logarithms of low-frequency measurement (InLF), and the natural logarithms of high-frequency measurement (InHF) of heart rate variability (HRV) were recorded. RESULTS: In both groups, NRS, ODI, SF-12 scores, and HRV at 2 weeks after treatment were improved and maintained for 6 months. Compared with the control group, more significant improvements were observed in the NRS and SF-12 scores at 1, 2, 3, and 6 months and in the ODI scores at 1 and 2 months in the SN group (P < 0.05). However, there was no significant difference between the groups in the ODI scores at 3 and 6 months. InLF and InHF in the SN group were higher than those in the control group at 3 and 6 months (P < 0.05). CONCLUSIONS: SNT relieved pain and improved quality of life and autonomic nerve activity, especially parasympathetic nerve, in patients with CNSLBP, without serious complications. TRIAL REGISTRATION: Chinese Clinical Trial Registry No. ChiCTR-OOC-17013237 . Registered on November 11, 2017.